FDPS and osteoporosis: Risedronate, which also acts on this pathway, and is commonly used to prevent osteoporosis, by blocking the enzyme FPP synthase, is also identified by both cohorts, and is ranked 4th by significance in cohort 2 (OR=0.567; CI 0.400 to 0.789), and 13th in cohort 1 (OR=0.705; CI 0.522 to 0.935).